MIRA PHARMACEUTICALS Business Summary

MIRA Pharmaceuticals, Inc. (MIRA) is a clinical-stage biopharmaceutical company primarily focused on the research and development of novel therapeutics for neurological and neuropsychiatric disorders. As of early 2026, the company remains pre-revenue, with a business model predicated on the long-term commercialization, licensing, and strategic partnering of its proprietary drug candidates. Its primary business segments are organized around its core pipeline: Ketamir-2, a novel oral NMDA receptor antagonist targeting chemotherapy-induced peripheral neuropathy (CIPN) and treatment-resistant depression; MIRA-55, a cannabinoid-based therapeutic for anxiety and cognitive decline; and SKNY-1, a recently acquired metabolic program for weight loss and nicotine addiction. MIRA competes directly with other neuroscience and cannabinoid-focused firms such as IGC Pharma, Voyager Therapeutics, and Humacyte. Within this landscape, MIRA positions itself as a high-agility, small-cap innovator leveraging artificial intelligence and proprietary receptor-targeting platforms to address significant unmet medical needs in the chronic pain and mental health sectors. The company is led by Chairman and CEO Erez Aminov, a seasoned executive with a background in accounting and venture capital who also serves as CEO of Telomir Pharmaceuticals. The leadership team includes Chief Financial Officer Alan Weichselbaum, who brings over 30 years of experience in capital markets and strategic advisory, and Chief Scientific Advisor Dr. Itzchak Angel, an industry veteran with 40 years of pharmaceutical development expertise. MIRA was co-founded by Dr. Adam Kaplin, a prominent neuropsychiatrist formerly of Johns Hopkins University. The company’s governance is supported by a board of directors that includes Matthew Pratt Whalen and Ned Macpherson, while its institutional investor base features notable firms such as Geode Capital Management and Citadel Advisors. This leadership pedigree combines deep clinical research experience with specialized financial expertise to navigate the complex regulatory pathways of the FDA and the broader biotechnology market.